1. Coppola, P., E. Kerwash and S. Cole, 2023. Use of physiologically based pharmacokinetic modeling for hepatically cleared drugs in pregnancy: Regulatory perspective. J. Clin. Pharmacol., 63: S62-S80.
   CrossRef  |  Direct Link  |  
2. Coppola, P., A. Butler, S. Cole and E. Kerwash, 2023. Total and free blood and plasma concentration changes in pregnancy for medicines highly bound to plasma proteins: Application of physiologically based pharmacokinetic modelling to understand the impact on efficacy. Pharmaceutics, Vol. 15. 10.3390/pharmaceutics15102455.
   CrossRef  |  Direct Link  |  
3. Serpi, M., V. Ferrari, C. McGuigan, E. Ghazaly and C. Pepper, 2022. Synthesis and characterization of NUC-7738, an aryloxy phosphoramidate of 3′-deoxyadenosine, as a potential anticancer agent. J. Med. Chem., 65: 15789-15804.
   CrossRef  |  Direct Link  |  
4. Coppola, P., E. Kerwash, J. Nooney, A. Omran and S. Cole, 2022. Pharmacokinetic data in pregnancy: A review of available literature data and important considerations in collecting clinical data. Front. Med., Vol. 9. 10.3389/fmed.2022.940644.
   CrossRef  |  Direct Link  |  
5. Coppola, P., E. Kerwash and S. Cole, 2022. The use of pregnancy physiologically based pharmacokinetic modeling for renally cleared drugs. J. Clin. Pharmacol., 62: S129-S139.
   CrossRef  |  Direct Link  |  
6. Slusarczyk, M., M. Serpi, E. Ghazaly, B.M. Kariuki, C. McGuigan and C. Pepper, 2021. Single diastereomers of the clinical anticancer ProTide agents NUC-1031 and NUC-3373 preferentially target cancer stem cells in vitro. J. Med. Chem., 64: 8179-8193.
   CrossRef  |  Direct Link  |  
7. Marshall, A., J. Kasturiarachchi, P. Datta, Y. Guo and E. Deltcheva et al., 2021. Author correction: Mir142 loss unlocks IDH2^R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Sci. Rep., Vol. 11. 10.1038/s41598-021-84578-y.
   CrossRef  |  Direct Link  |  
8. Kazmi, F., S. Nicum, R.L. Roux, L. Spiers and C. Gnanaranjan et al., 2021. A phase Ib open-label, dose-escalation study of NUC-1031 in combination with carboplatin for recurrent ovarian cancer. Clin. Cancer Res., 27: 3028-3038.
   CrossRef  |  Direct Link  |  
9. Coppola, P., E. Kerwash and S. Cole, 2021. Physiologically based pharmacokinetics model in pregnancy: A regulatory perspective on model evaluation. Front. Pediatr., Vol. 9. 10.3389/fped.2021.687978.
   CrossRef  |  Direct Link  |  
10. Vrettos, E.I., I.E. Valverde, A. Mascarin, P.N. Pallier and L. Cerofolini et al., 2020. Single peptide backbone surrogate mutations to regulate angiotensin GPCR subtype selectivity. Chem. A Eur. J., 26: 10690-10694.
    CrossRef  |  Direct Link  |  
11. Marshall, A., J. Kasturiarachchi, P. Datta, Y. Guo and E. Deltcheva et al., 2020. Mir142 loss unlocks IDH2^R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Sci. Rep., Vol. 10. 10.1038/s41598-020-76218-8.
    CrossRef  |  Direct Link  |  
12. Hay, J.L., J. O'Sullivan, E. Kerwash, A.R. Ilie and S.M. Cole, 2020. A review of clinical pharmacology deficiencies of European centralised drug marketing authorisation applications. Regul. Toxicol. Pharmacol., Vol. 118. 10.1016/j.yrtph.2020.104804.
    CrossRef  |  Direct Link  |  
13. Ghazaly, E.A., F. Miraki-Moud, P. Smith, C. Gnanaranjan and L. Koniali et al., 2020. Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. J. Biol. Chem., 295: 5496-5508.
    CrossRef  |  Direct Link  |  
14. Cole, S., P. Coppola, E. Kerwash, J. Nooney and S.P. Lam, 2020. Pharmacokinetic characterization to enable medicine use in pregnancy, the potential role of physiologically-based pharmacokinetic modeling: A regulatory perspective. CPT Pharmacometrics Syst. Pharmacol., 9: 547-549.
    CrossRef  |  Direct Link  |  
15. Cole, S., E. Kerwash and A. Andersson, 2020. A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. Drug Metab. Pharmacokinet., 35: 2-11.
    CrossRef  |  Direct Link  |  
16. Ali, S., R. Kjeken, C. Niederlaender, G. Markey and T.S. Saunders et al., 2020. The European medicines agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Oncologist, 25: e321-e327.
    CrossRef  |  Direct Link  |